Related Experiment Video
Updated: Apr 7, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
Intravenous immune globulin-related hemolysis: comparing two different methods for case assessment
Elaine Taylor1, Duc Vu1, Carole Legare1
1Marketed Biologics, Biotechnologies and Natural Health Products Bureau, Marketed Health Products Directorate, Health Canada, Ottawa, Ontario, Canada.
Transfusion
|July 16, 2015
Summary
Hemolysis is a rare risk with intravenous immune globulin (IVIG). This study compared two methods for identifying IVIG-associated hemolysis cases in Canada, finding case numbers varied by definition.
Area of Science:
- Pharmacovigilance
- Hematology
- Drug Safety
Background:
- Hemolysis is a rare but serious adverse event linked to intravenous immune globulin (IVIG) therapy.
- Accurate identification of these events is crucial for patient safety and understanding drug risks.
- This study examines case ascertainment methods for IVIG-associated hemolysis in Canada.
Purpose of the Study:
- To compare two distinct methods for identifying and confirming cases of hemolysis following IVIG administration.
- To analyze the trends in reported hemolytic reactions over a defined period.
- To assess the impact of different case definitions on reported adverse event numbers.
Main Methods:
- Retrospective analysis of adverse event reports submitted to Canada Vigilance between 2006 and 2012.
- Utilized standardized MedDRA queries for hemolytic disorders.
- Applied the Transfusion Transmitted Injuries Surveillance System (TTISS) algorithm for causality assessment and compared findings against the IVIG Hemolysis Pharmacovigilance Group case definition.
Main Results:
- Out of 942 IVIG adverse event reports, 313 (33%) involved hemolytic disorders.
- Using a modified TTISS definition, 226 cases were possibly related to IVIG; 69 met the stricter IVIG Hemolysis Pharmacovigilance Group definition.
- Reported "hemolytic disorder" cases did not correlate with the increasing distribution of IVIG over the study period.
Conclusions:
- The number of reported IVIG-associated hemolytic events fluctuated annually.
- The case definition employed significantly impacts the number of confirmed IVIG-associated hemolysis reports.
- Standardized case definitions are essential for consistent pharmacovigilance of IVIG adverse events.
